HK1211179A1 - Immunostimulatory oligonucleotide multimers - Google Patents

Immunostimulatory oligonucleotide multimers

Info

Publication number
HK1211179A1
HK1211179A1 HK15112153.1A HK15112153A HK1211179A1 HK 1211179 A1 HK1211179 A1 HK 1211179A1 HK 15112153 A HK15112153 A HK 15112153A HK 1211179 A1 HK1211179 A1 HK 1211179A1
Authority
HK
Hong Kong
Prior art keywords
immunostimulatory oligonucleotide
oligonucleotide multimers
multimers
immunostimulatory
oligonucleotide
Prior art date
Application number
HK15112153.1A
Other languages
English (en)
Chinese (zh)
Inventor
Sudhir Agrawal
Ekambar Kandimalla
Dong Yu
Original Assignee
Idera Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35600219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1211179(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idera Pharmaceuticals Inc filed Critical Idera Pharmaceuticals Inc
Publication of HK1211179A1 publication Critical patent/HK1211179A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/336—Modified G
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15112153.1A 2004-06-15 2015-12-09 Immunostimulatory oligonucleotide multimers HK1211179A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57998504P 2004-06-15 2004-06-15
US59936204P 2004-08-06 2004-08-06

Publications (1)

Publication Number Publication Date
HK1211179A1 true HK1211179A1 (en) 2016-05-20

Family

ID=35600219

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112153.1A HK1211179A1 (en) 2004-06-15 2015-12-09 Immunostimulatory oligonucleotide multimers

Country Status (20)

Country Link
US (4) US20060014713A1 (fr)
EP (2) EP2901856B1 (fr)
JP (1) JP4942646B2 (fr)
KR (1) KR20070028537A (fr)
AU (1) AU2005257938B2 (fr)
BR (1) BRPI0512110A (fr)
CA (1) CA2570786C (fr)
EE (1) EE200700003A (fr)
ES (1) ES2645158T3 (fr)
HK (1) HK1211179A1 (fr)
HR (1) HRP20070012A2 (fr)
HU (1) HUE036894T2 (fr)
IL (1) IL179973A0 (fr)
LV (1) LV13641B (fr)
MA (1) MA28976B1 (fr)
MX (1) MXPA06014915A (fr)
NO (1) NO20070263L (fr)
NZ (1) NZ552522A (fr)
RU (1) RU2007101039A (fr)
WO (1) WO2006002038A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
DK1009413T3 (da) * 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) * 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
KR100917101B1 (ko) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 플렉시블 금속적층체 및 그 제조방법
EP1322656B1 (fr) * 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation de l'activite immunostimulatrice d'analogues oligonucleotidiques immunostimulateurs par des modifications chimiques de position
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
US20030199466A1 (en) * 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
AR040996A1 (es) * 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
WO2004064782A2 (fr) * 2003-01-16 2004-08-05 Hybridon, Inc. Modulation des proprietes immunostimulatoires de composes a base d'oligonucleotides, a l'aide de dinucleotides immunostimulatoires modifies
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
JP2006528697A (ja) * 2003-05-16 2006-12-21 イデラ ファーマシューティカルズ インコーポレイテッド イムノマーを化学療法剤と組み合わせて用いる、癌の相乗的処置
CA2528597C (fr) * 2003-06-11 2014-08-05 Hybridon, Inc. Oligonucleotides d'immunomodulation stabilises
US20050013812A1 (en) * 2003-07-14 2005-01-20 Dow Steven W. Vaccines using pattern recognition receptor-ligand:lipid complexes
EP1648913A4 (fr) * 2003-07-15 2008-09-10 Idera Pharmaceuticals Inc Stimulation synergetique du systeme immunitaire a l'aide d'oligonucleotides immunostimulatoires et/ou de composes immunomeres conjugues a des cytokines et/ou a des agents chimiotherapeutiques ou a une radiotherapie
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
OA13278A (en) 2003-10-30 2007-01-31 Coley Pharm Gmbh C-Class oligonucleotide analogs with enhanced immunostimulatory potency.
CA2567789A1 (fr) * 2004-06-08 2006-08-03 Coley Pharmaceutical Gmbh Oligonucleotide abasique utilise en tant que plate-forme support pour un antigene ainsi qu'un agoniste et un antagoniste immunostimulatoire
US7498425B2 (en) * 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
CA2570786C (fr) * 2004-06-15 2013-05-28 Idera Pharmaceuticals, Inc. Multimeres oligonucleotidiques contenant des cpg modifies utilises pour stimuler le systeme immunitaire
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
JP2008531018A (ja) * 2005-02-24 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激性オリゴヌクレオチド
EP2179737B1 (fr) 2005-07-01 2013-08-14 Index Pharmaceuticals AB Modulation de la réponse aux steroides
ES2450593T3 (es) 2005-07-01 2014-03-25 Index Pharmaceuticals Ab Método inmunoestimulante
WO2007050034A1 (fr) 2005-10-28 2007-05-03 Index Pharmaceuticals Ab Composition et procede pour la prevention, le traitement et/ou l’attenuation d’une maladie inflammatoire
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CA2642152C (fr) * 2006-02-15 2016-11-01 Coley Pharmaceutical Gmbh Compositions et procedes pour formulations a base d'oligonucleotides
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
RU2468819C2 (ru) * 2007-08-01 2012-12-10 Идера Фармасьютикалз, Инк. Новые синтетические агонисты tlr9
US8883174B2 (en) 2009-03-25 2014-11-11 The Board Of Regents, The University Of Texas System Compositions for stimulation of mammalian innate immune resistance to pathogens
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
US9260719B2 (en) * 2013-01-08 2016-02-16 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (fr) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Adjuvant d'acide nucléique chiral ayant une activité anti-allergique, et agent anti-allergique
WO2015108047A1 (fr) 2014-01-15 2015-07-23 株式会社新日本科学 Adjuvant d'acide nucléique chiral possédant une activité d'induction d'immunité, et activateur d'induction d'immunité
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016044839A2 (fr) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions et méthodes pour traiter des infections virales par le biais de l'immunité innée stimulée en combinaison avec des composés antiviraux
EP3204040B1 (fr) * 2014-10-10 2021-12-08 Idera Pharmaceuticals, Inc. Traitement du cancer par agoniste(s) du tlr9 avec des inhibiteurs du point de contrôle
EP3220895B1 (fr) 2014-11-21 2022-08-31 Northwestern University Absorption cellulaire spécifique à une séquence de conjugués nanoparticulaires d'acides nucléiques sphériques
LU92821B1 (en) 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
IL292658A (en) 2016-09-15 2022-07-01 Idera Pharmaceuticals Inc Immune modulation with tlr9 agonists for cancer therapy
WO2018201090A1 (fr) 2017-04-28 2018-11-01 Exicure, Inc. Synthèse d'acides nucléiques sphériques à l'aide de fractions lipophiles
US11433131B2 (en) 2017-05-11 2022-09-06 Northwestern University Adoptive cell therapy using spherical nucleic acids (SNAs)
BR112022017973A2 (pt) * 2020-03-09 2022-11-16 Dynavax Tech Corp Imunização de reforço ativa contra tétano, difteria e coqueluche
BR112022017852A2 (pt) * 2020-03-09 2022-11-01 Dynavax Tech Corp Vacinas para herpes zoster compreendendo um agonista de tlr9

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
TW244371B (fr) 1992-07-23 1995-04-01 Tri Clover Inc
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US6346614B1 (en) 1992-07-23 2002-02-12 Hybridon, Inc. Hybrid oligonucleotide phosphorothioates
US5912332A (en) 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
EP1322656B1 (fr) * 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation de l'activite immunostimulatrice d'analogues oligonucleotidiques immunostimulateurs par des modifications chimiques de position
CA2430691A1 (fr) * 2000-12-27 2002-07-04 Dynavax Technologies Corporation Polynucleotides immunomodulants et methodes d'utilisation correspondantes
US20030199466A1 (en) 2001-06-21 2003-10-23 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same - ll
WO2003035836A2 (fr) * 2001-10-24 2003-05-01 Hybridon Inc. Modulation des proprietes immunostimulantes de composes a base d'oligonucleotides par presentation optimale d'extremites 5'
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
EP1625140A4 (fr) * 2002-12-23 2008-06-18 Dynavax Tech Corp Composes immunomodulateurs ramifies et leur procedes d'utilisation
WO2004064782A2 (fr) 2003-01-16 2004-08-05 Hybridon, Inc. Modulation des proprietes immunostimulatoires de composes a base d'oligonucleotides, a l'aide de dinucleotides immunostimulatoires modifies
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
CA2528597C (fr) * 2003-06-11 2014-08-05 Hybridon, Inc. Oligonucleotides d'immunomodulation stabilises
US20050004579A1 (en) 2003-06-27 2005-01-06 Schneider M. Bret Computer-assisted manipulation of catheters and guide wires
EP1648913A4 (fr) * 2003-07-15 2008-09-10 Idera Pharmaceuticals Inc Stimulation synergetique du systeme immunitaire a l'aide d'oligonucleotides immunostimulatoires et/ou de composes immunomeres conjugues a des cytokines et/ou a des agents chimiotherapeutiques ou a une radiotherapie
US7498425B2 (en) * 2004-06-15 2009-03-03 Idera Pharmaceuticals, Inc. Immunostimulatory oligonucleotide multimers
CA2570786C (fr) * 2004-06-15 2013-05-28 Idera Pharmaceuticals, Inc. Multimeres oligonucleotidiques contenant des cpg modifies utilises pour stimuler le systeme immunitaire

Also Published As

Publication number Publication date
ES2645158T3 (es) 2017-12-04
EE200700003A (et) 2007-06-15
BRPI0512110A (pt) 2007-10-23
CA2570786C (fr) 2013-05-28
WO2006002038A2 (fr) 2006-01-05
JP4942646B2 (ja) 2012-05-30
IL179973A0 (en) 2007-05-15
EP2901856B1 (fr) 2017-08-09
US20100166736A1 (en) 2010-07-01
KR20070028537A (ko) 2007-03-12
US20060014713A1 (en) 2006-01-19
US20080193437A1 (en) 2008-08-14
CA2570786A1 (fr) 2006-01-05
AU2005257938B2 (en) 2010-11-11
WO2006002038A3 (fr) 2008-07-17
RU2007101039A (ru) 2008-07-20
US8420615B2 (en) 2013-04-16
NO20070263L (no) 2007-03-09
HUE036894T2 (hu) 2018-08-28
US20070179103A1 (en) 2007-08-02
LV13641B (en) 2008-07-20
US7405285B2 (en) 2008-07-29
EP1765417A2 (fr) 2007-03-28
JP2008502688A (ja) 2008-01-31
EP1765417A4 (fr) 2009-03-25
MXPA06014915A (es) 2007-08-20
HRP20070012A2 (en) 2007-10-31
EP2901856A1 (fr) 2015-08-05
NZ552522A (en) 2009-04-30
AU2005257938A1 (en) 2006-01-05
MA28976B1 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
HK1211179A1 (en) Immunostimulatory oligonucleotide multimers
TWI365191B (en) Vaccine
EP1865925A4 (fr) Procede d administration orale
HK1082029A1 (en) Blower system
GB0409940D0 (en) Vaccine
PT1907574E (pt) Oligonucleótidos
IL173921A0 (en) Vaccine
GB0329146D0 (en) Vaccine
GB0411150D0 (en) Vaccine
HU3357U (en) Cushion
GB0305794D0 (en) Vaccine
GB0330079D0 (en) Vaccine
GB0413510D0 (en) Vaccine
GB0305793D0 (en) Vaccine
GB0426188D0 (en) DNA repeats
GB0428381D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB2419271B (en) Footwear comprising gripping means
AP2709A (en) An anti-theileriosis vaccine
GB0419918D0 (en) Vaccine
GB0406598D0 (en) Vaccine
GB0514898D0 (en) Introduction system
GB0417107D0 (en) Genes II
GB0301459D0 (en) Microrna
GB0317991D0 (en) Microrna

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230615